| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;113:2502-2508.)
© 2006 American Heart Association, Inc.
Coronary Heart Disease |
From the Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, Oregon (J.-P.B., J.L., D.E.L., H.L.-P., N.G.F., J.C., S.K.); and the Department of Pediatrics, Washington University, St. Louis, Missouri (A.D., E.M.H.).
Correspondence to Sanjiv Kaul, MD, Division of Cardiovascular Medicine, OHSU, UHN62, 3181 SW Sam Jackson Park Rd, Portland, OR 97239. E-mail kauls{at}ohsu.edu
Received August 12, 2005; de novo received March 16, 2006; revision received March 27, 2006; accepted March 31, 2006.
Background We hypothesized that nitroglycerin improves O2 delivery to ischemic tissue by altering erythrocyte rheology and O2 unloading through an increase in bioactive nitric oxide (NO) content.
Methods and Results Twelve dogs with resting flow-reducing single-vessel stenosis were studied at rest and during intracoronary infusion of nitroglycerin (0.3 to 0.6 µg · kg1 · min1). Half the dogs also had occlusion of the remote coronary artery to remove any collateral effects. Systemic and coronary hemodynamics, myocardial blood flow (MBF), whole blood viscosity (WB
), erythrocyte charge (EC) and mobility (EM), regional myocardial O2 delivery and consumption, and tissue O2 pressure (PO2) were measured. No changes in systemic hemodynamics were seen with nitroglycerin. Despite flow-limiting stenosis, MBF increased significantly in the central 25% of the ischemic bed, which was associated with an approximately 19% decrease in WB
. There was a good correlation (r=0.87) between the two. The decrease in WB
was associated with a decrease in EC and an increase in EM (r=0.83). The nitroglycerin-induced increase in tissue PO2 was disproportionate to the increase in MBF, indicating enhanced O2 unloading. Erythrocyte S-nitrosothiol content (reflecting mainly S-nitrosohemoglobin) was significantly higher for blood exposed in vitro to 0.1 µmol/L nitroglycerin or the NO donor SNAP, as compared with control (18.9±8.8 and 10.5±6.5 versus 2.6±0.5x105, P<0.05).
Conclusions The augmented MBF in the ischemic microcirculation during nitroglycerin administration occurs in tandem with increased erythrocyte S-nitrosothiol content, EM, and O2 unloading. These additional microvascular mechanisms may contribute to the powerful antiischemic effects of nitroglycerin, especially during low-flow states.
This article has been cited by other articles:
![]() |
B. Lima, G. K. W. Lam, L. Xie, D. L. Diesen, N. Villamizar, J. Nienaber, E. Messina, D. Bowles, C. D. Kontos, J. M. Hare, et al. Endogenous S-nitrosothiols protect against myocardial injury PNAS, April 14, 2009; 106(15): 6297 - 6302. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kaul Sonothrombolysis: A Universally Applicable and Better Way to Treat Acute Myocardial Infarction and Stroke? Who Is Going to Fund the Research? Circulation, March 17, 2009; 119(10): 1358 - 1360. [Full Text] [PDF] |
||||
![]() |
S. Kaul Myocardial Contrast Echocardiography: A 25-Year Retrospective Circulation, July 15, 2008; 118(3): 291 - 308. [Full Text] [PDF] |
||||
![]() |
S. Kaul and A. R. Jayaweera Determinants of microvascular flow Eur. Heart J., October 1, 2006; 27(19): 2272 - 2274. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |